Remove Insulin Remove Life Science Remove Pharma Companies
article thumbnail

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Delveinsight

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. It is also known as insulin-dependent diabetes.

article thumbnail

New Report Finds Whopping Increase in Pharma Cybersecurity Threats

XTalks

Findings from an analysis conducted by Constella Intelligence , a digital risk protection company, show widespread cybersecurity vulnerabilities that are costing pharma companies significantly. The report includes information on breaches, exposures and leaks in the pharma sphere.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices. That leaves three years for pharma companies to prepare.

Drugs 130
article thumbnail

Pharma TV Ad Spending Trends: Companies in the Top Ten this Week

XTalks

Novo Nordisk’s oral GLP-1 diabetes drug Rybelsus (semaglutide) has been up in the ranks this year in pharma TV ad spending, with the Danish pharma company having spent $19.9 The drug is a human glucagon-like peptide-1 (GLP-1) agonist that functions to increase insulin secretion from the pancreas. million and $18.6

Insulin 104
article thumbnail

Eli Lilly’s Tirzepatide Shows Promise in Treating Fatty Liver Disease

XTalks

Similar to tirzepatide, dulaglutide stimulates insulin secretion, inhibits glucagon release and promotes satiety. These candidate drugs are a small sample from a diverse array of GLP-1 receptor agonists that are being tested by pharma companies in varying formulations, dosing regimens and clinical profiles.

article thumbnail

LillyDirect: New Home Delivery Service for Eli Lilly’s Diabetes, Weight Loss and Migraine Drugs

XTalks

Related: Zepbound, Obesity Version of Eli Lilly’s Mounjaro, Finally Gets FDA Nod So far, LillyDirect provides support for 14 Lilly medicines, with 12 being different formulations and types of insulin. In addition to these and Zepbound, Lilly’s medication for migraine management, Emgality (galcanezumab), is also available through the website.

Drugs 59
article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

Cue Biopharma has an autoimmune disease collaboration with Merck, from which early data from a type 1 diabetes program was released earlier this year by the pharma company.

Protein 98